U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H16ClN3O
Molecular Weight 313.781
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMOXAPINE

SMILES

ClC1=CC2=C(OC3=C(C=CC=C3)N=C2N4CCNCC4)C=C1

InChI

InChIKey=QWGDMFLQWFTERH-UHFFFAOYSA-N
InChI=1S/C17H16ClN3O/c18-12-5-6-15-13(11-12)17(21-9-7-19-8-10-21)20-14-3-1-2-4-16(14)22-15/h1-6,11,19H,7-10H2

HIDE SMILES / InChI

Molecular Formula C17H16ClN3O
Molecular Weight 313.781
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Amoxapine is an antidepressant of the dibenzoxazepine class, chemically distinct from the dibenzazepines, dibenzocycloheptenes, and dibenzoxepines. It is designated chemically as 2-Chloro-11- (1-piperazinyl)dibenz[b,f ][1,4]oxazepine. Amoxapine is an antidepressant with a mild sedative component to its action. The mechanism of its clinical action in man is not well understood. In animals, amoxapine reduced the uptake of norepinephrine and serotonin and blocked the response of dopamine receptors to dopamine. Amoxapine is not a monoamine oxidase inhibitor. Amoxapine is absorbed rapidly and reaches peak blood levels approximately 90 minutes after ingestion. It is almost completely metabolized. The main route of excretion is the kidney. In vitro tests show that amoxapine binding to human serum is approximately 90%. In man, amoxapine serum concentration declines with a half-life of eight hours. However, the major metabolite, 8-hydroxyamoxapine, has a biologic half-life of 30 hours. Metabolites are excreted in the urine in conjugated form as glucuronides. Clinical studies have demonstrated that amoxapine has a more rapid onset of action than either amitriptyline or imipramine. The initial clinical effect may occur within four to seven days and occurs within two weeks in over 80% of responders.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
AMOXAPINE

Approved Use

Amoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation.

Launch Date

7.1487357E11
Primary
AMOXAPINE

Approved Use

Amoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation.

Launch Date

7.1487357E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
33.55 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMOXAPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
319 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMOXAPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.02 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMOXAPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMOXAPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Other AEs: Ataxia, Drowsiness...
Other AEs:
Ataxia (>1)
Drowsiness (14%)
Dry mouth (14%)
Constipation (12%)
Blurred vision (7%)
Anxiety (>1)
Insomnia (>1)
Nervousness (>1)
Nightmare (>1)
Restlessness (>1)
Palpitations (>1)
Tremor (>1)
Confusion (>1)
Excitement (>1)
Edema (>1)
Skin rash (>1)
Prolactin increased (>1)
Nausea (>1)
Dizziness (>1)
Headache (>1)
Fatigue (>1)
Weakness (>1)
Appetite excessive (>1)
Perspiration excessive (>1)
Accommodation disturbance (<1%)
Mydriasis (<1%)
Micturition disorder (<1%)
Urinary retention (<1%)
Nasal stuffiness (<1%)
Hypotension (<1%)
Hypertension (<1%)
Syncope (<1%)
Tachycardia (<1%)
Drug fever (<1%)
Urticaria (<1%)
Photosensitized (<1%)
Pruritus (<1%)
Vasculitis (<1%)
Hepatitis (<1%)
Tingling (<1%)
Tinnitus (<1%)
Disorientation (<1%)
Seizures (<1%)
Hypomania (<1%)
Numbness (<1%)
Incoordination (<1%)
Concentration impairment (<1%)
Hyperthermia (<1%)
Extrapyramidal symptoms (<1%)
Tardive dyskinesia (<1%)
Leukopenia (<1%)
Agranulocytosis (<1%)
Epigastric distress (<1%)
Vomiting (<1%)
Flatulence (<1%)
Abdominal pain (<1%)
Taste peculiar (<1%)
Diarrhea (<1%)
Impotence (<1%)
Menstrual irregularity (<1%)
Breast enlargement (<1%)
Inappropriate antidiuretic hormone secretion (<1%)
Galactorrhea (<1%)
Lacrimation (<1%)
Weight gain (<1%)
Weight loss (<1%)
Impaired liver function (<1%)
Painful ejaculation (<1%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Constipation 12%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Drowsiness 14%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Dry mouth 14%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Blurred vision 7%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Abdominal pain <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Accommodation disturbance <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Agranulocytosis <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Breast enlargement <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Concentration impairment <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Diarrhea <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Disorientation <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Drug fever <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Epigastric distress <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Extrapyramidal symptoms <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Flatulence <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Galactorrhea <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Hepatitis <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Hypertension <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Hyperthermia <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Hypomania <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Hypotension <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Impaired liver function <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Impotence <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Inappropriate antidiuretic hormone secretion <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Incoordination <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Lacrimation <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Leukopenia <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Menstrual irregularity <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Micturition disorder <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Mydriasis <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Nasal stuffiness <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Numbness <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Painful ejaculation <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Photosensitized <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Pruritus <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Seizures <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Syncope <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Tachycardia <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Tardive dyskinesia <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Taste peculiar <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Tingling <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Tinnitus <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Urinary retention <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Urticaria <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Vasculitis <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Vomiting <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Weight gain <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Weight loss <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Anxiety >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Appetite excessive >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Ataxia >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Confusion >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Dizziness >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Edema >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Excitement >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Fatigue >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Headache >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Insomnia >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Nausea >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Nervousness >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Nightmare >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Palpitations >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Perspiration excessive >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Prolactin increased >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Restlessness >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Skin rash >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Tremor >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Weakness >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: depression
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Amoxapine-associated acute renal failure.
1985 Jun
Amoxapine-induced cognitive impairment in two patients.
1987 Apr
Acute myocardial failure following amoxapine intoxication.
1988 Feb
Meta-analytical studies on new antidepressants.
2001
Availability of learned helplessness test as a model of depression compared to a forced swimming test in rats.
2001
[Delusional depression].
2001 Aug
Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine.
2001 Dec 27
Further characterization of 5-HT1A receptors in the goldfish retina: role of cyclic AMP in the regulation of the in vitro outgrowth of retinal explants.
2001 Mar
Glycine is taken up through GLYT1 and GLYT2 transporters into mouse spinal cord axon terminals and causes vesicular and carrier-mediated release of its proposed co-transmitter GABA.
2001 Mar
Painful ejaculation and urinary hesitancy in association with antidepressant therapy: relief with tamsulosin.
2002 Aug
The effects of tricyclic antidepressants on breast cancer risk.
2002 Jan 7
Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns.
2004 Apr 27
Risk of fetal exposure to tricyclic antidepressants.
2004 Oct
The pharmacological management of depression.
2005
Amoxapine as an atypical antipsychotic: a comparative study vs risperidone.
2005 Dec
Facilitation of spontaneous glutamate release by antidepressant drugs in rat locus coeruleus.
2005 Feb 10
Detection and treatment of akathisia in advanced cancer patients during adjuvant analgesic therapy with tricyclic antidepressants: case reports and review of the literature.
2007 Dec
Amoxapine as an antipsychotic: comparative study versus haloperidol.
2007 Dec
A fatal case of amoxapine poisoning under the influence of chronic use of psychotropic drugs.
2007 Mar
Differential distribution of glycine transporters in Müller cells and neurons in amphibian retinas.
2007 Mar-Apr
Prevalence and predictors of antidepressant use in a cohort of pregnant women.
2007 Sep
An autopsy case of poisoning with ethanol and psychotropic drugs.
2008 Apr
Functional expression of the glycine transporter 1 on bullfrog retinal cones.
2008 Nov 19
Amoxapine-induced tardive dyskinesia.
2009 Oct-Dec
A new strategy for antidepressant prescription.
2010
Direct agonist activity of tricyclic antidepressants at distinct opioid receptor subtypes.
2010 Jan
Drug-drug interaction between oxycodone and adjuvant analgesics in blood-brain barrier transport and antinociceptive effect.
2010 Jan
Tricyclic antidepressants and headaches: systematic review and meta-analysis.
2010 Oct 20
Patents

Sample Use Guides

Usual effective dosage is 200 to 300 mg daily. Three weeks constitutes an adequate period of trial providing dosage has reached 300 mg daily (or lower level of tolerance) for at least two weeks. If no response is seen at 300 mg, dosage may be increased, depending upon tolerance, up to 400 mg daily.
Route of Administration: Oral
Cells (mouse cortical neurons) were incubated with or without amoxapine varying concentrations of 10, 50, and 100 uM. At a concentration of 10 to 500 uM, amoxapine reversibly inhibited I(K) in a dose-dependent manner and modulated both steady-state activation and inactivation properties.
Substance Class Chemical
Created
by admin
on Sat Dec 17 01:42:53 UTC 2022
Edited
by admin
on Sat Dec 17 01:42:53 UTC 2022
Record UNII
R63VQ857OT
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AMOXAPINE
INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
AMOXAPINE [USP MONOGRAPH]
Common Name English
AMOXAPINE [VANDF]
Common Name English
2-CHLORO-11-(1-PIPERAZINYL)DIBENZ(B,F)(1,4)OXAZEPINE
Systematic Name English
NSC-759559
Code English
CL-67,772
Code English
DIBENZ(B,F)(1,4)OXAZEPINE, 2-CHLORO-11-(1-PIPERAZINYL)-
Systematic Name English
amoxapine [INN]
Common Name English
AMOXAPINE [USP-RS]
Common Name English
CL 67772
Code English
Amoxapine [WHO-DD]
Common Name English
CL 67,772
Code English
AMOXAPINE [MI]
Common Name English
AMOXAPINE [JAN]
Common Name English
LOXAPINE SUCCINATE IMPURITY, AMOXAPINE- [USP IMPURITY]
Common Name English
AMOXAPINE [ORANGE BOOK]
Common Name English
ASENDIN
Brand Name English
AMOXAPINE [MART.]
Common Name English
AMOXAPINE [USAN]
Common Name English
AMOXAPINE [USP IMPURITY]
Common Name English
CL-67772
Code English
Classification Tree Code System Code
WHO-VATC QN06AA17
Created by admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
NDF-RT N0000175752
Created by admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
WHO-ATC N06AA17
Created by admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
LIVERTOX NBK548520
Created by admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
NCI_THESAURUS C94727
Created by admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
Code System Code Type Description
DRUG CENTRAL
191
Created by admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
PRIMARY
EVMPD
SUB05479MIG
Created by admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
PRIMARY
LACTMED
Amoxapine
Created by admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
PRIMARY
RXCUI
722
Created by admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
PRIMARY RxNorm
FDA UNII
R63VQ857OT
Created by admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
PRIMARY
CAS
14028-44-5
Created by admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
PRIMARY
RS_ITEM_NUM
1031401
Created by admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
PRIMARY
IUPHAR
201
Created by admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
PRIMARY
MERCK INDEX
M1843
Created by admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
PRIMARY Merck Index
CHEBI
2675
Created by admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
PRIMARY
ECHA (EC/EINECS)
237-867-1
Created by admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
PRIMARY
INN
3049
Created by admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
PRIMARY
DRUG BANK
DB00543
Created by admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
PRIMARY
NSC
759559
Created by admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
PRIMARY
EPA CompTox
DTXSID7022598
Created by admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
PRIMARY
WIKIPEDIA
Amoxapine
Created by admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
PRIMARY
DAILYMED
R63VQ857OT
Created by admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
PRIMARY
PUBCHEM
2170
Created by admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
PRIMARY
MESH
D000657
Created by admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
PRIMARY
ChEMBL
CHEMBL1113
Created by admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
PRIMARY
NCI_THESAURUS
C47397
Created by admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
PRIMARY
Related Record Type Details
BINDER->LIGAND
Related Record Type Details
METABOLITE -> PARENT
METABOLITE -> PARENT
PARENT -> METABOLITE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC